UNITY Biotechnology (UBX)
(Delayed Data from NSDQ)
$1.51 USD
+0.01 (0.67%)
Updated Apr 29, 2024 02:23 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Income Statements
Fiscal Year end for UNITY Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 5 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 5 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 58 | 61 | 94 | 90 |
Income After Depreciation & Amortization | -45 | -58 | -57 | -94 | -90 |
Non-Operating Income | 7 | 1 | -1 | 1 | 7 |
Interest Expense | 2 | 4 | 3 | 1 | 0 |
Pretax Income | -40 | -60 | -61 | -94 | -82 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -40 | -60 | -61 | -94 | -82 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -40 | -60 | -61 | -94 | -82 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -39 | -54 | -52 | -87 | -88 |
Depreciation & Amortization (Cash Flow) | 6 | 3 | 5 | 7 | 2 |
Income After Depreciation & Amortization | -45 | -58 | -57 | -94 | -90 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 14.77 | 9.49 | 5.58 | 5.09 | 4.36 |
Diluted EPS Before Non-Recurring Items | -2.74 | -6.31 | -10.90 | -17.90 | -18.80 |
Diluted Net EPS (GAAP) | -2.70 | -6.31 | -10.90 | -18.40 | -18.80 |
Fiscal Year end for UNITY Biotechnology, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.12 | 14.93 | 11.96 | 10.66 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.12 | -14.93 | -11.96 | -10.66 |
Non-Operating Income | NA | 5.62 | 0.11 | 0.74 | 0.79 |
Interest Expense | NA | 0.00 | 0.47 | 0.98 | 1.00 |
Pretax Income | NA | -1.50 | -15.29 | -12.21 | -10.87 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.50 | -15.29 | -12.21 | -10.87 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.50 | -15.29 | -12.21 | -10.87 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 15.74 | 14.60 | 14.43 | 14.31 |
Diluted EPS Before Non-Recurring Items | NA | -0.53 | -0.67 | -0.85 | -0.76 |
Diluted Net EPS (GAAP) | NA | -0.04 | -1.05 | -0.85 | -0.76 |